Mechanisms for methotrexate chemotherapy-induced bone growth defects and protective effects of folinic acid supplementary treatment

Bone ◽  
2007 ◽  
Vol 40 (6) ◽  
pp. S87-S88
Author(s):  
C.J. Xian ◽  
J. Cool ◽  
M. Scherer ◽  
C. Macsai ◽  
C. Fan ◽  
...  
Keyword(s):  
Folinic Acid ◽  
Bone Growth ◽  
Protective Effects ◽  
Growth Defects ◽  
Supplementary Treatment ◽  
Methotrexate Chemotherapy

Cellular mechanisms for methotrexate chemotherapy-induced bone growth defects

Bone ◽  
2007 ◽  
Vol 41 (5) ◽  
pp. 842-850 ◽  
Author(s):  
Cory J. Xian ◽  
Johanna C. Cool ◽  
Michaela A. Scherer ◽  
Carmen E. Macsai ◽  
Chiaming Fan ◽  
...  
Keyword(s):  
Bone Growth ◽  
Cellular Mechanisms ◽  
Growth Defects ◽  
Methotrexate Chemotherapy

Damaging effects of chronic low-dose methotrexate usage on primary bone formation in young rats and potential protective effects of folinic acid supplementary treatment

Bone ◽  
2009 ◽  
Vol 44 (1) ◽  
pp. 61-70 ◽  
Author(s):  
Chiaming Fan ◽  
Johanna C. Cool ◽  
Michaela A. Scherer ◽  
Bruce K. Foster ◽  
Tetyana Shandala ◽  
...  
Keyword(s):  
Bone Formation ◽  
Folinic Acid ◽  
Low Dose ◽  
Protective Effects ◽  
Young Rats ◽  
Dose Methotrexate ◽  
Primary Bone ◽  
Supplementary Treatment ◽  
Damaging Effects

scholarly journals Release of CXCL12 from Apoptotic Skeletal Cells Contributes to Bone Growth Defects Following Dexamethasone Therapy in Rats

2020 ◽  
Vol 35 (8) ◽  
pp. 1612-1613
Author(s):  
Qian Tang ◽  
Yu‐Wen Su ◽  
Chia‐Ming Fan ◽  
Rosa Chung ◽  
Mohammadhossein Hassanshahi ◽  
...  
Keyword(s):  
Bone Growth ◽  
Growth Defects ◽  
Dexamethasone Therapy

scholarly journals Development of p-Coumaric Acid Analysis in Human Plasma and Its Clinical Application to PK/PD Study

2020 ◽  
Vol 10 (1) ◽  
pp. 108
Author(s):  
Hohyun Kim ◽  
Yunkyoung Choi ◽  
Yongwun An ◽  
Young-Rim Jung ◽  
Jin-Yong Lee ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Liquid Chromatography ◽  
Human Plasma ◽  
Bone Growth ◽  
Multiple Reaction Monitoring ◽  
Internal Standard ◽  
Control Group ◽  
Protective Effects ◽  
Coumaric Acid ◽  
Limit Of Quantitation

It has been recognized that p-Coumaric acid (p-CA) has protective effects as an antioxidant, anti-inflammatory agent. A sensitive and efficient Liquid Chromatography-Mass Spectrometry (LC-MS) method for maximum determination of p-CA in human plasma has been established using Ultra-performance liquid Chromatography-tandem mass Spectrometry (UPLC-MS/MS). This study provides the developed analysis of p-CA extracted from Bambusae Caulis in Taeniam (BC) to examine the improvement of the treatment p-CA, IGF-1 and Osteocalcin level in human children which are important factors on the growth of children’s height through Pharmacokinetics/Pharmacodynamics (PK/PD) model. p-CA and internal standard in a plasma sample were detected by the Multiple Reaction Monitoring (MRM) scan mode with positive ion detection. The sample participating in the study was made of 34 subjects (placebo = 18, treatment = 16). The subjects were enrolled to be randomized to the control group and BC group. Randomized subjects took tested treatment twice a day, three capsules with oral administration (258 mg/capsule) each time after a meal. Standard calibration curves (reproducibility) were constructed and the lower limit of quantitation (LLOQ) for p-CA was found to be 0.2 ng/mL on injection of the sample into the UPLC-MS/MS system. Accuracy and precision were evaluated and the intra-accuracy was 99.2–103.8% with precision of 1.0–5.6% and inter-accuracy was 99.6–108.4% and precision of 1.3–6.4% for p-CA. The method has been successfully applied to PK/PD studies of p-CA in human plasma. The p-CA, BC in Taeniam extract increased the level of IGF-1 and Osteocalcin, and changed the height from baseline, which suggested that the p-CA could play an important role in longitudinal bone growth. Therefore, the p-CA extracted from BC in Taeniam might be a good alternative medicine to growth hormone (GH) therapy.

Sign in / Sign up

Export Citation Format

Share Document